

Case Data Byte

Law Firm Glancy Prongay & Murray LLP
Company Name AnaptysBio, Inc.
Stock Symbol ANAB
Class Period October 10, 2017 and November 7, 2019
Lead Plaintiff Motion Deadline May 26, 2020
Contact Attorney Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067
Contact Phone 310-801-2829
Contact Email shareholders@glancylaw.com
Press Release <https://www.glancylaw.com/news-faqs/anab-case-urgent-may-26-2020-deadline-to-file-le>

Case Summary

On March 26, 2018, AnaptysBio revealed data from an interim analysis of a Phase 2a trial for etokimab in adult patients with peanut allergies. Though the Company reported improvement among patients who received a single dose of etokimab compared to patients dosed with a placebo, later that day, an analyst from RBC Capital Markets issued a report that questioned the accuracy of that data.

On this news, the Company's share price fell \$6.31 per share, or over 5%, to close at \$107.52 per share on March 27, 2018, thereby injuring investors.

About the Company

AnaptysBio is a clinical-stage biotechnology company developing

first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development of our proprietary product candidates, and where applicable, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights.

Yahoo Finance

<https://finance.yahoo.com/quote/anab>

Website

<https://www.anaptysbio.com/>

Join Action Link

<https://www.glancylaw.com/cases-application/join-case/anaptysbio-inc/>